Literature DB >> 18215167

Induction of actin cytoskeleton rearrangement by methyl okadaate--comparison with okadaic acid.

Natalia Vilariño1, Isabel R Ares, Eva Cagide, M Carmen Louzao, Mercedes R Vieytes, Takeshi Yasumoto, Luis M Botana.   

Abstract

Methyl okadaate is a derivative of the lipophilic polyether okadaic acid (OA), a well-known inducer of apoptosis. OA inhibits Ser/Thr protein phosphatases (PPs), among them types 1 and 2A (PP1 and PP2A), whereas methyl okadaate lacks PP1/PP2A inhibitory activity in vitro. As progressive loss of neuronal cytoarchitecture is a major event that precedes neuronal death, in this work we studied comparatively the effects of both toxins on actin cytoskeleton organization in human neuroblastoma cells by filamentous actin (F-actin) labeling with the specific dye Oregon Green 514 Phalloidin. Neither methyl okadaate nor OA modified the amount of F-actin per cell. However, confocal microscopy imaging showed that methyl okadaate induced reorganization of actin cytoskeleton, loss of the typical flattened morphology and adoption of a round shape, and a reduction in the number of neurites, with a consequent loss of cell attachment. These effects were identical to those induced by OA, although methyl okadaate potency was approximately 10-fold lower. In order to investigate the role of membrane potential and cytosolic Ca2+ concentration in morphological changes induced by these toxins, the cells were stained with bis-(1,3-dibutylbarbituric acid)-trimethine oxonol and fura-2. No toxin effect was detected on membrane potential or calcium influx, indicating that these two signals are not responsible for cytoskeletal/morphological change induction. Methyl okadaate induced an increase of Ser/Thr phosphorylation of cellular proteins detected by western blot, showing similar phosphorylation profiles to OA. Our data suggest that methyl okadaate is an active compound that shares a pharmacological target with OA that may be a Ser/Thr phosphatase, probably different from PP1 and PP2A.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215167     DOI: 10.1111/j.1742-4658.2008.06256.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  6 in total

1.  Palytoxin induces functional changes of anion transport in red blood cells: metabolic impact.

Authors:  Silvana Ficarra; Annamaria Russo; Francesca Stefanizzi; Mario Mileto; Davide Barreca; Ersilia Bellocco; Giuseppina Laganà; Ugo Leuzzi; Bruno Giardina; Antonio Galtieri; Ester Tellone
Journal:  J Membr Biol       Date:  2011-07-06       Impact factor: 1.843

2.  The methyl ester of okadaic acid is more potent than okadaic acid in disrupting the actin cytoskeleton and metabolism of primary cultured hepatocytes.

Authors:  Begoña Espiña; M Carmen Louzao; Eva Cagide; Amparo Alfonso; Mercedes R Vieytes; Takeshi Yasumoto; Luis M Botana
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

3.  Experimental basis for the high oral toxicity of dinophysistoxin 1: a comparative study of DSP.

Authors:  Diego A Fernández; M Carmen Louzao; María Fraga; Natalia Vilariño; Mercedes R Vieytes; Luis M Botana
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

4.  Serotonin involvement in okadaic acid-induced diarrhoea in vivo.

Authors:  M Carmen Louzao; Celia Costas; Paula Abal; Toshiyuki Suzuki; Ryuichi Watanabe; Natalia Vilariño; Cristina Carrera; Andrea Boente-Juncal; Carmen Vale; Mercedes R Vieytes; Luis M Botana
Journal:  Arch Toxicol       Date:  2021-06-20       Impact factor: 5.153

5.  Effect of okadaic acid on cultured clam heart cells: involvement of MAPkinase pathways.

Authors:  Houda Hanana; Hélène Talarmin; Jean-Pierre Pennec; Mickael Droguet; Julie Morel; Germaine Dorange
Journal:  Biol Open       Date:  2012-09-25       Impact factor: 2.422

Review 6.  Is protein phosphatase inhibition responsible for the toxic effects of okadaic Acid in animals?

Authors:  Rex Munday
Journal:  Toxins (Basel)       Date:  2013-02-04       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.